/PRNewswire/ Provention Bio, Inc. (Nasdaq: PRVB) (the "Company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated.
Companies collaborating to expand access to TZIELD (teplizumab-mzwv), the first approved disease-modifying therapy for type 1 diabetes RED BANK, N.J., Feb. 13, 2023 /PRNewswire/ Provention Bio
The FDA approval of teplizumab for the delay of type 1 diabetes highlights the need to cost-effectively identify those at risk who could potentially receive it.
By Bhanvi Satija (Reuters) - Provention Bio said on Thursday the U.S. Food and Drug Administration had approved the use of its drug teplizumab in thos.